|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 276, Issue 24, 21262-21271, June 15, 2001
From the The neurotransmitter serotonin
controls a wide range of biological systems, including its own
synthesis and release. As the rate-limiting enzyme in serotonin
biosynthesis, tryptophan hydroxylase (TPH) is a potential target for
this autoregulation. Using the serotonergic neuron-like CA77
cell line, we have demonstrated that treatment with a
5-hydroxytryptamine autoreceptor agonist, CGS 12066A, can lower
TPH mRNA levels and promoter activity. We reasoned that this
repression might involve inhibition of MAP kinases, since 5-HT1
receptors can increase mitogen-activated protein (MAP) kinase
phosphatase levels. To test this hypothesis, we first showed that the
TPH promoter can be activated 20-fold by mitogen-activated
extracellular-signal regulated kinase kinase kinase (MEKK), an
activator of MAP kinases. This activation was then blocked by CGS
12066A. The maximal MAP kinase and CGS repression regulatory region was
mapped to between Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc. This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||